Study guide
3.4 Pharmacokinetics & Narrow Therapeutic Index Drugs
PSI Equivalence Examination Third Country Qualification Recognition
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & TCQR Framework
1.1 TCQR Pathway and PSI Equivalence Exam Structure 1.2 PSI Core Competency Framework and MPharm Standard 1.3 Irish Healthcare System & Pharmacy Environment
2 Chapter 2: Pharmaceutical Calculations
2.1 Paediatric & Adult Dose Calculations 2.2 Percentage Strengths, Ratio Strengths & PPM Conversions 2.3 Dilutions, Alligations & Reconstitution 2.4 Infusion Rates, Syringe Drivers & Opioid Equianalgesic Conversions
3 Chapter 3: Pharmacology & Applied Pharmacokinetics
3.1 Receptor Pharmacology & Autonomic Nervous System 3.2 Cardiovascular & Renal Pharmacology 3.3 Central Nervous System & Antimicrobial Pharmacology 3.4 Pharmacokinetics & Narrow Therapeutic Index Drugs
4 Chapter 4: Basic Science & Pharmaceutics
4.1 Physicochemical Properties of Drugs 4.2 Dosage Form Formulation & Excipients 4.3 Drug Stability, Degradation & Bioequivalence
5 Chapter 5: Pharmacy Practice & Dispensing Workflow
5.1 Prescription Validation & Dispensing Workflow 5.2 Patient Counselling & Medicines Safety 5.3 Responding to Symptoms & Minor Ailments 5.4 Primary Care Schemes & Community Services
6 Chapter 6: Irish Pharmacy Law & Professional Ethics
6.1 Pharmacy Act 2007 & PSI Governance 6.2 Medicinal Products Regulations 6.3 Controlled Drugs Legislation & Misuse of Drugs Regulations 6.4 Professional Ethics & Code of Conduct
7 Chapter 7: Clinical Therapeutics & Disease State Management
7.1 Respiratory & Endocrine Therapeutics 7.2 Cardiovascular & Gastrointestinal Therapeutics 7.3 Infections, Antimicrobial Stewardship & Public Health 7.4 Special Populations & Complex Care
8 Chapter 8: OSCE & Practical Clinical Communication Skills
8.1 OSCE Station Structure & Core Competencies 8.2 Structured Patient Consultations & Devices Counselling 8.3 Prescriber Interventions, Ethical Dilemmas & Professional Judgement
3.4 Pharmacokinetics & Narrow Therapeutic Index Drugs
Key Takeaways Explain This Topic AI
Systemic bioavailability (F) quantifies the proportion of active drug entering systemic circulation; high first-pass hepatic extraction substantially reduces oral bioavailability despite complete gastrointestinal absorption.
Volume of distribution (Vd) correlates total body drug content to plasma concentration; drugs with high lipid solubility and tissue binding exhibit large Vd values exceeding total body water (>42 L).
Elimination half-life (t1/2) is directly proportional to volume of distribution and inversely proportional to clearance (t1/2 = 0.693 × Vd / Cl); steady-state plasma concentrations are attained after 4 to 5 half-lives of regular dosing.
Narrow therapeutic index (NTI) medications require therapeutic drug monitoring (TDM) using precise trough blood samples drawn immediately prior to the next scheduled dose once steady state is achieved.
Phenytoin displays Michaelis-Menten non-linear elimination kinetics at therapeutic concentrations, where enzyme saturation causes disproportionately large, unpredictable increases in plasma concentration following minor dosage adjustments.
Last updated: July 2026
3.4 Pharmacokinetics & Narrow Therapeutic Index Drugs
Quick Reference: Pharmacokinetics (PK) quantitatively defines drug movement into, through, and out of the body via Absorption, Distribution, Metabolism, and Excretion (ADME). Mastery of PK equations, elimination rates, steady-state kinetics, and Therapeutic Drug Monitoring (TDM) protocols is critical for managing narrow therapeutic index (NTI) drugs safely.
Mathematical modeling of PK parameters enables clinical pharmacists to individualize dosing regimens, optimize therapeutic efficacy, and prevent severe adverse drug reactions.
- Fundamental Pharmacokinetic Parameters: ADME
- 1. Absorption & Bioavailability ( F F F )
Bioavailability ( F F F ) is the fraction of an administered drug dose that reaches the systemic circulation in an active, unchanged form. F = AUC oral AUC IV × 100 % F = \frac{\text{AUC}_{\text{oral}}}{\text{AUC}_{\text{IV}}} \times 100\% F = AUC IV AUC oral × 100%
Intravenous (IV) Route: F = 1.0 F = 1.0 F = 1.0 (100% bioavailability by definition).
Oral Route Factors: Incomplete GI mucosal absorption, intestinal efflux transporters (P-glycoprotein), and first-pass hepatic metabolism (CYP3A4 extraction) reduce F F F (e.g., morphine F ≈ 30 % F \approx 30\% F ≈ 30% , propranolol F ≈ 25 % F \approx 25\% F ≈ 25% ).
2. Distribution & Volume of Distribution ( V d V_d V d )
Volume of Distribution ( V d V_d V d ) is a theoretical volume relating the total amount of drug in the body ( D body D_{\text{body}} D body ) to its measured plasma concentration ( C p C_p C p ): V d = D body C p V_d = \frac{D_{\text{body}}}{C_p} V d = C p D body
Low V d V_d V d ( < 5 L < 5\text{ L} < 5 L or 0.07 L/kg 0.07\text{ L/kg} 0.07 L/kg ): Confined to vascular plasma space. Highly plasma protein-bound (e.g., Warfarin V d ≈ 8 L V_d \approx 8\text{ L} V d ≈ 8 L ). Acidic drugs bind primarily to Albumin .
Moderate V d V_d V d ( 10 – 42 L 10–42\text{ L} 10–42 L ): Distributed throughout extracellular or total body water (e.g., Gentamicin V d ≈ 0.25 L/kg V_d \approx 0.25\text{ L/kg} V d ≈ 0.25 L/kg ). Basic drugs bind to Alpha-1-Acid Glycoprotein .
High V d V_d V d ( > 42 L > 42\text{ L} > 42 L or > 0.7 L/kg > 0.7\text{ L/kg} > 0.7 L/kg ): Extensively sequestered in peripheral tissue, fat, or cell membranes (e.g., Digoxin V d ≈ 7 L/kg V_d \approx 7\text{ L/kg} V d ≈ 7 L/kg , Chloroquine V d > 100 L/kg V_d > 100\text{ L/kg} V d > 100 L/kg ). Hemodialysis is ineffective for high V d V_d V d drug clearance.
3. Metabolism (Biotransformation)
Phase I Reactions: Oxidation, reduction, hydrolysis. Introduced or unmasked polar functional groups ( − O H , − N H 2 , − S H -OH, -NH_2, -SH − O H , − N H 2 , − S H ). Mediated predominantly by microsomal Cytochrome P450 (CYP) enzymes.
Major Isoforms: CYP3A4 (metabolizes >50% of drugs), CYP2D6, CYP2C9, CYP2C19, CYP1A2.
Inducers ( ↓ \downarrow ↓ drug concentration): Rifampicin, Carbamazepine, Phenytoin, St John's Wort, Phenobarbital.
Inhibitors ( ↑ \uparrow ↑ toxicity risk): Ketoconazole, Erythromycin, Clarithromycin, Ciprofloxacin, Omeprazole, Grapefruit juice (intestinal CYP3A4).
Phase II Reactions: Conjugation with endogenous polar substrates (Glucuronidation, Sulfation, Acetylation, Glutathione conjugation) producing inactive, hydrophilic metabolites excreted renally.
4. Clearance ( C l Cl Cl ) & Elimination
Clearance ( C l Cl Cl ) is the volume of plasma completely cleared of drug per unit of time (e.g., mL/min or L/h). Total systemic clearance is additive: C l total = C l renal + C l hepatic + C l other Cl_{\text{total}} = Cl_{\text{renal}} + Cl_{\text{hepatic}} + Cl_{\text{other}} C l total = C l renal + C l hepatic + C l other
Renal elimination rate depends on Glomerular Filtration Rate (GFR), active tubular secretion, and passive tubular reabsorption (influenced by urinary pH: alkalinisation accelerates weak acid excretion).
- Quantitative Kinetics & Dosing Regimens
- First-Order vs. Zero-Order Kinetics
First-Order Kinetics (Linear PK):
A constant fraction (percentage) of drug is eliminated per unit time.
Elimination rate is directly proportional to plasma concentration ( C p C_p C p ).
Half-life ( t 1 / 2 t_{1/2} t 1/2 ) remains constant regardless of dose.
Zero-Order Kinetics (Non-Linear / Capacity-Limited PK):
A constant amount (mass) of drug is eliminated per unit time due to saturation of metabolic enzymes or clearance mechanisms.
Clearance decreases and t 1 / 2 t_{1/2} t 1/2 increases as plasma concentration rises.
Clinical Examples: Phenytoin (at therapeutic ranges), Ethanol , high-dose Aspirin .
- Key Quantitative Equations
- Elimination Rate Constant ( k e k_e k e ): k e = C l V d k_e = \frac{Cl}{V_d} k e = V d Cl
Elimination Half-Life ( t 1 / 2 t_{1/2} t 1/2 ): t 1 / 2 = ln ( 2 ) k e = 0.693 × V d C l t_{1/2} = \frac{\ln(2)}{k_e} = \frac{0.693 \times V_d}{Cl} t 1/2 = k e ln ( 2 ) = Cl 0.693 × V d
Time to Steady-State ( C s s C_{ss} C ss ): Achieved after 4 to 5 half-lives ( 4 − 5 × t 1 / 2 4-5 \times t_{1/2} 4 − 5 × t 1/2 ) of constant dosing.
Maintenance Dose ( M D MD M D ): M D = C s s × C l × τ F MD = \frac{C_{ss} \times Cl \times \tau}{F} M D = F C ss × Cl × τ (where τ \tau τ is the dosing interval)
Loading Dose ( L D LD L D ): L D = C s s × V d F LD = \frac{C_{ss} \times V_d}{F} L D = F C ss × V d (Used to immediately attain therapeutic concentrations for drugs with long t 1 / 2 t_{1/2} t 1/2 )
Therapeutic Drug Monitoring (TDM) & Narrow Therapeutic Index (NTI) Drugs
Narrow Therapeutic Index drugs possess a narrow margin between efficacy and life-threatening toxicity ( T I < 2 TI < 2 T I < 2 ). TDM optimizes individual patient dosing via precise serum concentration monitoring.
Drug Name Target Therapeutic Range TDM Sampling Timing Key Toxicities & Clinical Signs Key Pharmacokinetic & Monitoring Considerations
Digoxin 0.8 – 2.0 ng/mL (0.5–0.9 ng/mL in heart failure) Trough: ≥ 6 − 8 \ge 6-8 ≥ 6 − 8 hours post-dose (to allow distribution phase) Cardiac arrhythmias (PVCs, AV block), nausea/vomiting, xanthopsia (yellow-green visual halos), confusion High V d V_d V d (7 L/kg). Hypokalemia , hypomagnesemia, and hypercalcemia potentiate toxicity. Excreted renally (reduce dose in CKD)
Lithium 0.6 – 1.0 mmol/L (0.8–1.2 mmol/L in acute mania) Trough: Exactly 12 hours post-evening dose Fine tremor → \rightarrow → coarse tremor, ataxia, dysarthria, seizures, nephrogenic diabetes insipidus, hypothyroidism Excreted 100% renally. Cleared identically to sodium; dehydration, thiazides, and NSAIDs increase lithium levels and toxicity
Gentamicin Traditional: Peak 5–10 mg/L, Trough <2 mg/L; Once-Daily: Trough < 0.5–1.0 mg/L Peak: 30 min post-infusion; Trough: Immediately pre-dose Ototoxicity (vestibular damage, tinnitus, irreversible hearing loss), nephrotoxicity (acute tubular necrosis) Hydrophilic ( V d ≈ 0.25 L/kg V_d \approx 0.25\text{ L/kg} V d ≈ 0.25 L/kg ). Excreted renally via GFR. Once-daily extended-interval dosing utilizes concentration-dependent killing ( C max / MIC C_{\text{max}}/\text{MIC} C max / MIC )
Vancomycin Trough: 10 – 20 mg/L (15–20 mg/L for severe MRSA endocarditis/pneumonia; AUC/MIC 400–600) Trough: Within 30 min prior to steady-state dose (4th dose) Nephrotoxicity, ototoxicity, Red Man Syndrome (infusion reaction) Renally cleared. Trough levels guide dosing to ensure efficacy and minimize nephrotoxicity
Theophylline 10 – 20 mg/L (5–15 mg/L modern respiratory guidance) Peak/Trough: 4–8 hours post-dose (oral liquid/plain) or trough Severe tachyarrhythmias, intractable seizures, refractory emesis Metabolized by CYP1A2. Non-linear kinetics at upper range. Smoking induces CYP1A2; ciprofloxacin and erythromycin inhibit clearance
Phenytoin Total: 10 – 20 mg/L (Free un-bound: 1.0–2.0 mg/L) Trough: Immediately pre-dose at steady state Nystagmus, ataxia, dysarthria, lethargy, gingival hyperplasia, hirsutism, peripheral neuropathy Michaelis-Menten non-linear kinetics ( V max , K m V_{\text{max}}, K_m V max , K m ). Highly protein bound (90%). Hypoalbuminemia requires concentration correction (Sheiner-Tozer equation)
Clinical TDM Sampling Rules
Steady-State Confirmation: Always sample after achieving steady state ( 4 − 5 × t 1 / 2 4-5 \times t_{1/2} 4 − 5 × t 1/2 ), unless acute toxicity is suspected.
Trough Sampling: Draw blood samples within 30 minutes immediately before administering the next scheduled dose for most drugs (vancomycin, gentamicin, phenytoin).
Distribution Phase Delay: For drugs with prolonged distribution phases (digoxin, lithium), delay sampling until tissue distribution equilibrium is complete (6–8 hours for digoxin, 12 hours for lithium).